Gast ::
| Hauptseite > Publikationsdatenbank > Uncoupling sodium channel dimers restores the phenotype of a pain‐linked Na v 1.7 channel mutation > print |
| Hauptseite > Publikationsdatenbank > Uncoupling sodium channel dimers restores the phenotype of a pain‐linked Na v 1.7 channel mutation > print |
| 001 | 886070 | ||
| 005 | 20210220152101.0 | ||
| 024 | 7 | _ | |a 10.1111/bph.15196 |2 doi |
| 024 | 7 | _ | |a 0007-1188 |2 ISSN |
| 024 | 7 | _ | |a 0366-0826 |2 ISSN |
| 024 | 7 | _ | |a 1476-5381 |2 ISSN |
| 024 | 7 | _ | |a 2056-8177 |2 ISSN |
| 024 | 7 | _ | |a 2128/26036 |2 Handle |
| 024 | 7 | _ | |a altmetric:86186603 |2 altmetric |
| 024 | 7 | _ | |a pmid:32663327 |2 pmid |
| 024 | 7 | _ | |a WOS:000563939100001 |2 WOS |
| 037 | _ | _ | |a FZJ-2020-04256 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Rühlmann, Annika H. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Uncoupling sodium channel dimers restores the phenotype of a pain‐linked Na v 1.7 channel mutation |
| 260 | _ | _ | |a Malden, MA |c 2020 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1613744876_5811 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background and PurposeThe voltage‐gated sodium channel Nav1.7 is essential for adequate perception of painful stimuli. Mutations in the encoding gene, SCN9A, cause various pain syndromes in humans. The hNav1.7/A1632E channel mutant causes symptoms of erythromelalgia and paroxysmal extreme pain disorder (PEPD), and its main gating change is a strongly enhanced persistent current. On the basis of recently published 3D structures of voltage‐gated sodium channels, we investigated how the inactivation particle binds to the channel, how this mechanism is altered by the hNav1.7/A1632E mutation, and how dimerization modifies function of the pain‐linked mutation.Experimental ApproachWe applied atomistic molecular simulations to demonstrate the effect of the mutation on channel fast inactivation. Native PAGE was used to demonstrate channel dimerization, and electrophysiological measurements in HEK cells and Xenopus laevis oocytes were used to analyze the links between functional channel dimerization and impairment of fast inactivation by the hNav1.7/A1632E mutation.Key ResultsEnhanced persistent current through hNav1.7/A1632E channels was caused by impaired binding of the inactivation particle, which inhibits proper functioning of the recently proposed allosteric fast inactivation mechanism. hNav1.7 channels form dimers and the disease‐associated persistent current through hNav1.7/A1632E channels depends on their functional dimerization status: Expression of the synthetic peptide difopein, a 14‐3‐3 inhibitor known to functionally uncouple dimers, decreased hNav1.7/A1632E channel‐induced persistent currents.Conclusion and ImplicationsFunctional uncoupling of mutant hNav1.7/A1632E channel dimers restored their defective allosteric fast inactivation mechanism. Our findings support the concept of sodium channel dimerization and reveal its potential relevance for human pain syndromes. |
| 536 | _ | _ | |a 551 - Functional Macromolecules and Complexes (POF3-551) |0 G:(DE-HGF)POF3-551 |c POF3-551 |f POF III |x 0 |
| 536 | _ | _ | |a Multiscale simulations of voltage-gated sodium channel complexes and clusters (jics42_20191101) |0 G:(DE-Juel1)jics42_20191101 |c jics42_20191101 |f Multiscale simulations of voltage-gated sodium channel complexes and clusters |x 1 |
| 536 | _ | _ | |a MOLECULAR MODELLING OF BIFUNCTIONAL MEMBRANE TRANSPORT PROTEINS (jics40_20190501) |0 G:(DE-Juel1)jics40_20190501 |c jics40_20190501 |f MOLECULAR MODELLING OF BIFUNCTIONAL MEMBRANE TRANSPORT PROTEINS |x 2 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Körner, Jannis |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hausmann, Ralf |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Bebrivenski, Nikolay |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Neuhof, Christian |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Detro‐Dassen, Silvia |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Hautvast, Petra |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Benasolo, Carène A. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Meents, Jannis |0 0000-0001-9423-0453 |b 8 |
| 700 | 1 | _ | |a Machtens, Jan-Philipp |0 P:(DE-Juel1)156429 |b 9 |u fzj |
| 700 | 1 | _ | |a Schmalzing, Günther |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Lampert, Angelika |0 0000-0001-6319-6272 |b 11 |e Corresponding author |
| 773 | _ | _ | |a 10.1111/bph.15196 |g Vol. 177, no. 19, p. 4481 - 4496 |0 PERI:(DE-600)2029728-2 |n 19 |p 4481 - 4496 |t British journal of pharmacology |v 177 |y 2020 |x 1476-5381 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/886070/files/bph.15196.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/886070/files/bph.15196.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:886070 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)156429 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-551 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-500 |4 G:(DE-HGF)POF |v Functional Macromolecules and Complexes |x 0 |
| 913 | 2 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-02-26 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRIT J PHARMACOL : 2018 |d 2020-02-26 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2020-02-26 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-02-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |d 2020-02-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-02-26 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-02-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BRIT J PHARMACOL : 2018 |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-02-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-02-26 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)IBI-1-20200312 |k IBI-1 |l Molekular- und Zellphysiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-82)080012_20140620 |k JARA-HPC |l JARA - HPC |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)IBI-1-20200312 |
| 980 | _ | _ | |a I:(DE-82)080012_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|